SIS
LCTX icon

Sound Income Strategies’s Lineage Cell Therapeutics LCTX Stock Holding History

Sound Income Strategies’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4
Closed -$7 – 2545
2025
Q3 		$7 Hold
4
– – ﹤0.01% 1686
2025
Q2 		$4 Buy
+4
New +$2 ﹤0.01% 1600

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
RA
Raffles Associates New York $115M AUM 35.69% 1-Year Est. Return
Comerica Bank
Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sound Income Strategies's LCTX Position: Q4 2025 in Review

Sound Income Strategies sold out of Lineage Cell Therapeutics (LCTX) in Q4 2025, closing a stake of 4 shares — an estimated $7 sold.

Sound Income Strategies first reported a position in LCTX in Q2 2025 and held it in 2 quarters. The position peaked at $7 in Q3 2025. 123 funds tracked by Wall St. Rank hold LCTX as of Q4 2025.

  • Sound Income Strategies reported no remaining Lineage Cell Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sound Income Strategies sold 4 Lineage Cell Therapeutics shares in Q4 2025, an estimated $7.
  • Sound Income Strategies first reported a position in Lineage Cell Therapeutics in Q2 2025 and held it in 2 quarters.
  • Sound Income Strategies's Lineage Cell Therapeutics position peaked at $7 in Q3 2025.
  • 123 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2025.

Based on Sound Income Strategies's 13F filing for Q4 2025, filed 21 Jan 2026.